Acquisition - June 5, 2015
Cortendo Buys Endocrine Disease Treatments
Swedish-American biotech company Cortendo is buying a pair of Phase II treatments for acromegaly for a total of $35 million, according to FierceBiotech. Cortendo agreed to pay Aspireo Pharmaceuticals $30 million for somatoprim, or DG3173, a treatment designed to block the excess growth hormone production that characterizes acromegaly. The drug showed positive results on hormone […]
Companies - March 23, 2015
Cortendo Names Board Members
John H. Johnson has been appointed chairman of the Cortendo AB board of directors and Richard Kollender named a director. The appointments were proposed by the nomination committee and approved by shareholders during the Extraordinary General Meeting on March 17. “We welcome the additions of John and Rich to Cortendo’s board of directors,” said Matthew […]
In a new job - August 11, 2014
New CEO for Cortendo
Gothenburg-based company Cortendo has appointed Matthew Pauls as President and Chief Executive Officer. Prior to joining Cortendo, Mr. Pauls was Chief Commercial Officer of Insmed, Inc, a publicly traded biopharmaceutical company. Mr. Pauls has also worked at Shire Pharmaceuticals, most recently as Senior Vice President, Head of Global Commercial Operations. Mr. Pauls also held positions […]
